Category Archives: Blog

TfR1/TFRC/CD71: From Iron Metabolism to a Gateway for Brain Delivery

With updated Phase III clinical data released by Roche in 2025, trontinemab has emerged as a leading example of TfR1-mediated blood–brain barrier delivery, achieving high amyloid clearance with low ARIA-E incidence in Alzheimer’s disease patients. By exploiting TfR1-dependent transcytosis, this bispecific antibody highlights TfR1/CD71 not only as a central regulator of iron metabolism, but also as a highly promising gateway for CNS therapeutic delivery.

Blog 2026-05-08

From BD to Clinical Milestones The Core Trends in Autoimmune Diseases Finally Emerge in 2026 Q1

In Q1 2026, progress in the autoimmune field is no longer characterized by fragmented innovation, but by systematic breakthroughs centered on a handful of core targets. Starting from these targets, the following provides a detailed overview of the most representative BD deals and clinical milestones within each category.

Blog , 2026-04-23

Therapeutic Targets from the Perspective of Blood–Brain Barrier (BBB) Shuttling Who Can Truly Deliver Drugs into the Brain

The blood–brain barrier (BBB) is emerging as a critical gateway for drug delivery to the central nervous system. With agents such as Trontinemab and Pabinafusp alfa advancing into clinical validation, BBB shuttling mechanisms are reshaping the criteria for assessing target druggability.

Blog , 2026-04-23

Sortase A Protease: A Versatile Enzymatic Tool for Site-Specific Protein Engineering

Site-specific protein ligation is increasingly critical in applications such as protein labeling, antibody conjugation, and multifunctional fusion protein construction. Sortase A (SrtA), a transpeptidase from Gram-positive bacteria, is widely used for its LPXTG motif recognition and efficient ligation with oligoglycine substrates, with engineered variants further improving catalytic efficiency and control.

Blog 2026-04-16

$40B in March 2026: From ADHD to TCEs-What Big Pharma Is Really Chasing

Ahead of the 2026 AACR Annual Meeting, global business development (BD) activity surged in March, showing clear structural trends. On one hand, large-scale M&A and licensing deals continued to concentrate in oncology and immunology. On the other hand, emerging technology platforms such as AI-driven drug discovery, targeted protein degradation (TPD), and multispecific antibodies gained significant momentum. Meanwhile, Chinese biotech companies deepened their participation in global dealmaking through NewCo structures and regional licensing.
This report systematically organizes key March transactions by therapeutic area to highlight the core logic and emerging hotspots in innovative drug BD.

Blog 2026-04-15
Top ADC Targets in Focus key Trends in Antibody-Drug Conjugate Development at AACR 2026

[AACR 2026] Top ADC Targets in Focus Key Trends in Antibody-Drug Conjugate Development

From abstract frequency, the top ADC targets at AACR 2026 rank approximately as follows: HER2 (64) > TROP2 (33) > EGFR (29) > PD-L1 (18) > NECTIN4 (17) > B7-H3/CD276 (15) > FOLR1 (12) > c-Met (11) > CDH17 (10) > DLL3 (8) > CLDN18.2 (7). Below is a concise overview of these key ADC targets.

Blog 2026-03-31
GPCR Target Landscape: From CXCR4 to GPRC5D Which GPCR Targets Are Gaining Momentum in oncology at 2026 AACR

[AACR 2026] From CXCR4 to GPRC5D: Which GPCR Targets Are Gaining Momentum in Oncology

AACR 2026 trends clearly indicate a turning point. GPCR-related research is rapidly expanding beyond traditional small-molecule receptor modulation into tumor microenvironment regulation, Treg depletion, antibody-drug conjugates (ADCs), bispecific antibodies, multispecific biologics, and radiopharmaceuticals.

Blog , 2026-03-31

GPR84: A Key Medium-Chain Fatty Acid Receptor Linking Metabolism and Immunity

Immunometabolism has emerged as a key frontier in drug discovery, with GPR84 gaining attention as a medium-chain fatty acid receptor linking metabolism and immune regulation. It plays a dual role by enhancing macrophage phagocytosis and anti-tumor immunity, while also promoting inflammation through NLRP3 inflammasome activation. Despite its clear biological significance and involvement in the tumor microenvironment, the clinical development of GPR84-targeted therapies remains challenging, highlighting the need for a deeper understanding of its structure, signaling, and therapeutic potential.

Blog 2026-03-27

SLC7A11xCT: A New Multidimensional Battlefield in Tumor Therapy from Ferroptosis to Immunotherapy

SLC7A11 (xCT), the functional subunit of the cystine/glutamate antiporter System xc⁻, plays a central role in tumor redox balance by mediating cystine uptake for glutathione (GSH) synthesis, thereby protecting cancer cells from oxidative stress and ferroptosis. Recent studies published in *Cell* and *Nature* in 2025 further revealed that SLC7A11 can also trigger disulfidptosis under specific metabolic conditions, highlighting a context-dependent vulnerability in cancer cells. These findings position SLC7A11 at the intersection of ferroptosis, metabolic stress, and emerging cell death pathways, making it a promising therapeutic target. This article summarizes the structural features of SLC7A11, its regulatory role in ferroptosis, and recent advances in related therapeutic strategies.

Blog 2026-03-09

February BD Roundup: Global Biopharma Deals Accelerate Despite Holiday Slowdown

Although February coincided with the Lunar New Year holiday and a seasonal slowdown in market activity, global biopharma business development remained highly active. From RNAi licensing and CAR-T acquisitions to antibody collaborations and AI-driven drug discovery alliances, multiple headline transactions were announced in rapid succession, many reaching multi-billion-dollar values.

Blog 2026-03-04